For the quarter ending 2026-03-31, AVBP has $349,295K in assets. $25,315K in debts. $62,103K in cash and cash equivalents.
| Balance Sheets | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Cash and cash equivalents | 62,103 | 45,540 | 112,672 | 112,765 |
| Short-term investments | 264,277 | 267,281 | 187,594 | 122,922 |
| Prepaid expenses and other current assets | 22,320 | 20,076 | 20,952 | 14,462 |
| Total current assets | 348,700 | 332,897 | 321,218 | 250,149 |
| Long-term investments | - | - | 5,108 | 18,793 |
| Right of use assets - operating leases | 370 | 13 | 49 | 85 |
| Deferred offering costs | 69 | 69 | - | - |
| Other assets | 156 | 190 | 180 | 479 |
| Total assets | 349,295 | 333,169 | 326,555 | 269,506 |
| Accounts payable | 8,727 | 5,934 | 5,933 | 4,060 |
| Accrued expenses | 16,169 | 19,997 | 15,569 | 15,478 |
| Operating lease liabilities | 99 | 14 | 56 | 98 |
| Total current liabilities | 24,995 | 25,945 | 21,558 | 19,636 |
| Operating lease liabilities, net of current amount | 320 | - | - | - |
| Total liabilities | 25,315 | 25,945 | 21,558 | 19,636 |
| Common stock 0.0001 par value, 200,000,000 shares authorized 45,308,941 and 42,452,251 shares issued and outstanding at march 31, 2026 and december 31, 2025, respectively | 5 | 4 | 4 | 4 |
| Additional paid-in capital | 772,206 | 711,847 | 673,884 | 584,003 |
| Retained Earnings Accumulated Deficit | - | - | - | -334,100 |
| Accumulated deficit | -447,961 | -404,641 | -369,097 | -334,119 |
| Accumulated other comprehensive income (loss) | -270 | 14 | 206 | -18 |
| Total stockholders' equity | 323,980 | 307,224 | 304,997 | 249,870 |
| Total liabilities and stockholders' equity | 349,295 | 333,169 | 326,555 | 269,506 |
ArriVent BioPharma, Inc. (AVBP)
ArriVent BioPharma, Inc. (AVBP)